NEWS: BGF, SNIB and Scottish Enterprise invest £8 million in Elasmogen

PRESS RELEASE click here: BGF, Scottish National Investment Bank and Scottish Enterprise join forces to invest £8m in Aberdeen biologics company Elasmogen

Elasmogen is progressing next generation biologics for inflammatory, autoimmune diseases and oncology

Elasmogen exploits its unique soloMER™ technology as drugs in small, simple, and stable formats that are amenable to site-specific and systemic delivery.

Elasmogen is progressing life-extending therapies for those patients that have been let down by current small molecule and systemic monoclonal antibody approaches.

converge-challenge  biotrinity  SLA life sciences

Biofit winner.png (002) Summit awards winner (002)